期刊
DRUG DISCOVERY TODAY
卷 24, 期 4, 页码 1044-1058出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2019.02.012
关键词
-
资金
- Portuguese Foundation for Science and Technology (FCT)
- PhD Program in Medicines and Pharmaceutical Innovation (i3DU) by the European Social Fund of the European Union [PD/BD/135460/2017]
- national funds FCT/MCTES
- FCT [UID/MULTI/00070/2013, UID/QUI/50006/2013-POCI/01/0145/FEDER/007265, PTDC/QEQ-MED/1890/2014, 3599]
- European Community Fund FEDER [3599-PPCDT]
- Fundação para a Ciência e a Tecnologia [PD/BD/135460/2017, PTDC/QEQ-MED/1890/2014, UID/Multi/00070/2013] Funding Source: FCT
Treatment of triple-negative breast carcinoma (TNBC) remains an unmet medical need with no targeted therapy available to date. Accounting for 10-30% of all human breast cancer tumors, this mammary carcinoma subtype has a particularly poor prognosis owing to its high metastatic potential, aggressive biology and limited pharmacological treatment options. Platinum chemotherapeutics are the mainstay therapy in patients with TNBC but their clinical use is limited by severe toxicity and acquired resistance. Palladium-based complexes are appealing alternative metal-based drugs because of significant similarities regarding structure and coordination chemistry with the platinum agents. This review summarizes the knowledge gathered so far on 121 Pd(II) complexes, emphasizing their anticancer activity and putative pharmacological targets toward TNBC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据